PC
CNST

Polar Capital’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Polar Capital’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,196
Closed -$216K – 329
2020
Q2 		$216K Buy
+7,196
New +$259K ﹤0.01% 272

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMV
Venrock Management V Palo Alto, California $719M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Polar Capital's CNST Position: Q3 2020 in Review

Polar Capital sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2020, closing a stake of 7,196 shares — an estimated $216K sold.

Polar Capital first reported a position in CNST in Q2 2020 and held it in 1 quarter. The position peaked at $216K in Q2 2020. 119 funds tracked by Wall St. Rank hold CNST as of Q3 2020.

  • Polar Capital reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Polar Capital sold 7,196 Constellation Pharmaceuticals, Inc. shares in Q3 2020, an estimated $216K.
  • Polar Capital first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Polar Capital's Constellation Pharmaceuticals, Inc. position peaked at $216K in Q2 2020.
  • 119 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.